Caffeine Half-Life — Body Handbook

Sleep · §177

Caffeine Half-Life

Caffeine has a half-life — the time your body takes to clear half of what you drank — and yours might be two hours or it might be ten. The average is around five, which means an average drinker's 2 pm coffee is still meaningfully active at 10 pm; a slow metaboliser's is still there at midnight. Most people sleeping worse than they want to are sleeping on residual caffeine from earlier in the day and don't realise it. The fix is timing, not abstinence — and which side of the average you sit on can move the cut-off by hours.

Do · Daily Evidence Moderate Chapter Sleep

Move your last caffeine to morning-only and most people's sleep gets a noticeable repair within a week — easier onset, more deep sleep, less 3 am waking. The daytime energy lift follows two weeks later, once you stop drinking caffeine to fix the sleep that caffeine broke. If you take the pill, recently quit smoking, are pregnant, or get anxious from a single cup, you're a slow metaboliser and the cut-off should be earlier still. It costs nothing; the hardest part is the first three days of saying no to the 3 pm coffee.

Caffeine wakes you up by blocking adenosine, the molecule your brain builds up over the waking day to signal you're tired Bjorness 2009. Your liver clears caffeine through an enzyme called CYP1A2 Thorn 2012, and how fast that enzyme works is mostly your genes plus a handful of life modifiers. The average healthy non-smoker takes about five hours to drop a single dose by half Carrillo and Benitez 2000. A fast metaboliser does it in two. A slow one takes ten.

Half-life is the time to halve the dose, not eliminate it. After one half-life half of what you drank is still there; after three, an eighth; you need three to five half-lives to be properly clear. And the sleep effect outlasts even the blood levels, because the adenosine receptors stay quietly suppressed after the caffeine itself has left the bloodstream Landolt 1995.

Concrete: an average five-hour-half-life drinker has a coffee at 2 pm. At 7 pm, half of it is still on the adenosine receptors. At midnight, a quarter. A slow metaboliser drinking the same coffee still has half. The fast metaboliser is clear by dinner. Same coffee, three different bedtimes.

Does timing actually move sleep?

The cleanest evidence is a controlled sleep-lab trial that has been hard to dismiss since it published. People drinking moderate-to-heavy doses in the afternoon, even hours before bed, lose objectively-measured sleep — and usually don't notice.

The lingering-receptor finding goes further. A single morning dose of 200 mg measurably altered slow-wave activity in the overnight EEG thirteen hours later — long after the caffeine had cleared the blood Landolt 1995. The systematic review pulling these together documents the same pattern across the broader trial literature: dose-dependent reductions in total sleep time and slow-wave sleep, longer sleep onset, and habitual users consistently underestimating their own sleep damage compared to what the polysomnography shows Clark and Landolt 2017.

Are you a slow metaboliser?

Several groups are slow metabolisers without needing a genetic test.

The pill. Combined oral contraceptives roughly double caffeine half-life — the oestrogen in them blocks CYP1A2 Abernethy and Todd 1985.
Pregnancy. By the third trimester, clearance is about a third of what it was pre-pregnancy Knutti 1981.
Just quit smoking. Smoking sped your caffeine clearance up by about half. It renormalises in four to six days, which is why coffee suddenly keeps you wired when you quit Carrillo and Benitez 2000.
Anxious from one cup. About a third of people carry a variant in the adenosine receptor gene (ADORA2A) that makes caffeine more anxiogenic regardless of how fast they clear it Childs 2008. The signal: a single coffee leaves you jittery, restless, or with palpitations.
Genetic slow. Roughly 10–15% of European-ancestry adults carry the slow (CC) version of the main CYP1A2 polymorphism Sachse 1999. Consumer pharmacogenomic panels report it.

Genotyping is cheap, but the behaviour test is better: move your cut-off back two hours for two weeks and watch what happens to your sleep. That captures the combined effect of genes, the pill, smoking status, current medications, and your real-world dose, all at once.

The loop you might be stuck in

Average metaboliser, 3 pm coffee on autopilot, in bed by 11 — most of the office-working population. Caffeine is still on the adenosine receptors that should be reading high adenosine and giving you deep sleep. The sleep tracker won't show it; the polysomnograph would. Slow-wave sleep is down, fragmentation is up, total sleep is short by half an hour or so — usually unfelt at the time Clark and Landolt 2017. The next morning you're tireder than you should be. You reach for the wake-up coffee to fix it. By 3 pm you're sagging, and you reach for the afternoon coffee to push through. The fatigue and the fix have the same source, and you can't tell them apart. The afternoon coffee is masking a sleep debt — and stealing the very night's sleep you'd use to repay it.

Years of that, and the baseline shifts. The morning coffee is mandatory; the afternoon coffee is mandatory. People close to you mention you sleep badly; you start calling yourself a bad sleeper. If you also carry the anxiety variant, you've spent years assuming the low-grade dread is your personality when a real chunk of it is yesterday's dose still working on you Childs 2008.

The cut-off

For an average metaboliser, cut caffeine off at least eight hours before bed — so if you're aiming to be asleep by 11, no caffeine after 3 pm. That's the population default that gets you out of the worst of the Drake 2013 effect for a standard dose Drake 2013. If you're a slow metaboliser by any of the criteria above, pull it back further: morning-only, with nothing after 10 am. Keep the daily total under 400 mg (roughly four standard coffees) and any single dose under 200 mg — that is the EFSA safety ceiling for healthy adults EFSA 2015.

If you don't know your category, run the two-week test. Move the cut-off back two hours from wherever it currently sits, hold it there for fourteen days, and watch what happens to your sleep onset and how you feel at 3 pm. If the 3 pm crash goes quiet by week two, you were medicating sleep with caffeine and now you don't need to.

When to cut more than just time

Some situations need a smaller dose, not just an earlier dose.

Pregnancy. The regulator ceiling drops to 200 mg/day on safety grounds independent of sleep, and slowed clearance makes the timing rule strict — morning-only at most EFSA 2015 Knutti 1981.
Diagnosed panic disorder or generalised anxiety, particularly if a moderate coffee triggers symptoms. Cessation is the standard recommendation, not just earlier timing Childs 2008.
Starting fluvoxamine (used for OCD and depression) or a course of ciprofloxacin. Both block CYP1A2 strongly enough that your normal caffeine becomes a much bigger functional dose — fluvoxamine alone can extend caffeine's half-life from five hours to thirty or more Jeppesen 1996 Carrillo and Benitez 2000.
Uncontrolled hypertension, recent heart attack, or known severe arrhythmia. Ask your clinician where to set the dose — caffeine acutely raises stress hormones and renin Robertson 1978.

What most people get wrong

"I can drink coffee right up to bedtime and still sleep fine." Subjective sleep onset is a weak detector. The Drake 2013 subjects reported relatively normal sleep on caffeine that the EEG showed was an hour shorter Drake 2013. Habitual users lose the felt signal first; the damage to sleep architecture persists.

"Half-life is five hours, so I'm clear after five hours." No — half-life is the time to halve the dose, not eliminate it. After five hours, half the coffee is still on board. Properly clear is three to five half-lives, and the receptor effect on sleep architecture outlasts even that Landolt 1995.

"I'm tolerant, so caffeine doesn't disrupt my sleep any more." Tolerance builds for the alertness and anxiety effects. It barely builds for the sleep effect — chronic drinkers still show measurable polysomnography damage on caffeine nights Weibel 2020 Clark and Landolt 2017.

What you get back

The first sober night usually reads differently on a tracker — shorter time to sleep, more slow-wave time, fewer 3 am wakings Landolt 1995. The felt change lags the measurement by a week or two, because habitual users have recalibrated their baseline expectations down. Most people notice the morning starts to feel different by day three or four: still tired, but a different tired — less crash, less brain fog, less of the late-afternoon dip.

By the end of two weeks, the afternoon coffee that used to be mandatory is optional. The 3 pm crash that drove it goes quiet because the sleep underneath is now doing its job Clark and Landolt 2017. Your partner notices you fall asleep faster; the person sharing your house mentions you seem less wired at 9 pm. Months in, the daily caffeine total tends to drop on its own — the morning dose is doing all the work it needs to. If you carry the ADORA2A anxiety variant, the steady low-grade dread you'd attributed to your personality starts to lift within hours of the last cup and stays lifted as long as the cut-off holds Childs 2008.

The longer-horizon payoffs are smaller and slower, but they're real: the skin and face benefit that follows from years of properly-restorative sleep, and the long-tail mortality and disease-risk reductions that track chronic adequate sleep at the population level. Neither is the headline reason to fix the timing; both come along for the ride.

The catch is the first three days. Heavy habit cut hard gives you a withdrawal headache, sluggishness, mild low mood. It passes by day three or four. A two-week clean trial is the minimum window that lets the steady-state benefit show through; cutting and reinstating after 48 hours just shows you the withdrawal.

If timing isn't the whole story you wanted: the full caffeine-and-sleep picture (slow-wave sleep, sleep debt, circadian alignment); coffee as a beverage rather than a caffeine vehicle (polyphenols, chlorogenic acids); caffeine as a performance enhancer for endurance and strength training; chronic caffeine withdrawal as a clinical syndrome; the broader genetics of how people respond to stimulants.

Related in the handbook

Worsens / aggravates

— An afternoon coffee masks sleep debt and steals the night's sleep you'd use to repay it.

— Caffeine's half-life is why the coffee protocol caps the dose and times the last cup before afternoon.
— Since caffeine is the one nootropic that reliably works, its half-life is exactly what decides whether it helps or hurts.
— Like a late coffee, an evening drink quietly degrades the sleep you don't blame it for.
— If you nap in the afternoon, mind your last coffee — caffeine's long half-life can wreck the night the nap was meant to set up.
— How fast you clear caffeine is largely genetic — the same metaboliser difference these tests read.

Substance and claimed effects

Caffeine is the world's most-used psychoactive substance, an adenosine-receptor antagonist absorbed almost completely from the gut and metabolised in the liver, primarily by the CYP1A2 enzyme Thorn 2012. The substance of this entry is not caffeine in the abstract but the half-life dimension of caffeine pharmacokinetics: the time it takes a single dose to fall to half its peak plasma concentration, and the considerable inter-individual variation in that number. Population mean is roughly 5 hours in healthy non-smoking adults, but credible clinical sources document a real-world range of about 2 to 10+ hours depending on CYP1A2 genotype, smoking, oral contraceptive use, pregnancy, and concurrent medications Carrillo and Benitez 2000. The claimed effects this entry covers are the downstream consequences of that variation: timing of evening cut-off for sleep onset and sleep architecture Drake 2013 Landolt 1995, anxiety expression in genetically sensitive consumers Alsene 2003 Childs 2008, and downstream daytime energy, focus and mood mediated through restored sleep Clark and Landolt 2017.

Evidence by addressing question

mechanism

Caffeine is absorbed within 30–45 minutes of ingestion and reaches peak plasma concentration around the same time EFSA 2015. About 95% of clearance proceeds through hepatic CYP1A2, which N-3-demethylates caffeine to paraxanthine; minor pathways via CYP2A6, NAT2 and xanthine oxidase handle the remainder Thorn 2012. The CYP1A2 gene at 15q24 carries a common intron-1 polymorphism (rs762551, often labelled CYP1A2*1F) where the variant A allele is associated with higher inducibility. Homozygous AA "rapid metabolisers" clear caffeine roughly twice as fast as homozygous CC "slow metabolisers" after smoking or other CYP1A2 induction; in non-smokers without induction the genotype-only effect on baseline clearance is smaller but measurable Sachse 1999 Cornelis 2011. The pharmacodynamic side runs through adenosine antagonism: caffeine competitively blocks A₁ and A_2A receptors, suppressing the buildup of sleep pressure that adenosine normally signals over the waking day Bjorness and Greene 2009 Reichert 2022. The longer caffeine stays above its effective receptor-occupancy threshold (commonly cited as roughly half-saturating around 100 mg plasma exposure), the longer adenosine signalling stays attenuated. That means a slow metaboliser drinking a 2 pm latte still has clinically meaningful receptor occupancy at 10 pm; a rapid metaboliser has cleared most of it. The variation in half-life is therefore not a curiosity — it directly maps to how long after a dose adenosine remains blocked at the cortex.

evidence

The pharmacokinetic-variation literature is older and reasonably mature. Knutti 1981 documented the dramatic pregnancy effect — caffeine half-life rising from ~3 hours pre-pregnancy to ~10.5 hours by the third trimester in the same individuals, a finding since replicated across cohorts Knutti 1981. Abernethy and Todd 1985 showed oral contraceptives roughly double caffeine half-life via CYP1A2 inhibition by ethinyl oestradiol Abernethy and Todd 1985; this is reinforced by general CYP1A2 inhibition data on ethinyl oestradiol/gestodene preparations Granfors 2005. Smoking is the largest induction effect — about 50% reduction in half-life in heavy smokers, normalising over 4–6 days after cessation Carrillo and Benitez 2000. Fluvoxamine, ciprofloxacin and fluconazole inhibit CYP1A2 strongly; fluvoxamine 100 mg/day raises caffeine AUC roughly 5-fold and extends half-life from ~5 to ~30+ hours Jeppesen 1996 Carrillo and Benitez 2000. On the sleep-architecture side, Drake 2013 is the canonical RCT: 400 mg caffeine ingested at bedtime, 3 hours before bed, and 6 hours before bed all produced significant disruption of total sleep time measured by polysomnography, with the 6-hour-before condition still costing roughly an hour of objective sleep Drake 2013. Landolt 1995 showed that a single 200 mg morning dose taken roughly 13 hours before bedtime still measurably altered overnight EEG spectral power — fewer slow waves, reduced sleep efficiency — establishing that effects on sleep architecture persist well past plasma clearance because the receptor occupancy and homeostatic system take longer to recover Landolt 1995. Clark and Landolt 2017 reviewed the broader RCT and epidemiological literature: consistent dose-dependent reductions in total sleep time and slow-wave sleep, increased sleep latency, and the consistent finding that habitual users underestimate their own sleep impairment compared to objective polysomnography Clark and Landolt 2017. The anxiety side is anchored by Alsene 2003 and Childs 2008: variants in ADORA2A (the A_2A receptor gene), particularly rs5751876, are associated with higher caffeine-induced anxiety at typical doses (150–450 mg), with carriers more likely to report panicky responses to caffeine independent of clearance speed Alsene 2003 Childs 2008.

protocol

The conservative population default — 8 to 10 hours of caffeine-free time before bedtime — derives from the Drake 2013 finding that even 6 hours of clearance is insufficient to prevent measurable sleep disruption for the average drinker Drake 2013. Multiplying observed half-life by 5 gives ≥97% clearance: for a typical 5-hour half-life that is ~25 hours of full washout, but useful sleep onset is achievable once plasma is below the threshold that produces receptor occupancy >25%, which is roughly 3 half-lives or 15 hours after a typical 200 mg dose. The practical translation: an average metaboliser drinking 200 mg of caffeine at noon still has receptor-relevant levels at 11 pm; cutting off by 10 am puts most of the clearance before bedtime. Slow metabolisers (oral contraceptive users, non-smoking CC homozygotes, pregnant women, those taking fluvoxamine/ciprofloxacin) should target morning-only or eliminate entirely. Fast metabolisers (heavy smokers, AA homozygotes) can tolerate later cut-offs without measurable polysomnography effects, but the felt-experience boundary still tends to be around 6–8 hours pre-bed Clark and Landolt 2017. EFSA's safety opinion settled on 400 mg/day for healthy adults and 200 mg single doses with no near-bedtime intake, which is the regulatory expression of the same logic EFSA 2015.

contraindications

Pregnancy is the strongest individual modifier of half-life: by the third trimester caffeine clearance is roughly one-third of pre-pregnancy values, and EFSA recommends no more than 200 mg/day during pregnancy on safety grounds independent of sleep Knutti 1981 EFSA 2015. Anxiety disorders, panic disorder and ADORA2A genotype carriers tolerate caffeine poorly; reduction or elimination is a standard recommendation in those populations Childs 2008. Concurrent fluvoxamine (SSRI used for OCD/depression) and ciprofloxacin (fluoroquinolone antibiotic) require either caffeine cessation or major dose reduction during the course of treatment, because plasma AUC can rise 5–10-fold Jeppesen 1996 Carrillo and Benitez 2000. Untreated atrial fibrillation, uncontrolled hypertension, and known severe arrhythmia warrant clinician input — caffeine acutely raises plasma catecholamines and renin activity, although the long-term cardiovascular effect in habituated users is modest Robertson 1978.

misconceptions

Three persistent ones. First: "I can drink coffee right up to bedtime and still sleep fine." Subjective sleep onset is a weak detector of caffeine effects; polysomnography in habitual users shows reduced slow-wave sleep, increased sleep fragmentation and decreased sleep efficiency that the drinker does not consciously perceive Drake 2013 Clark and Landolt 2017. Second: "Half-life is 5 hours so I'm clear after 5 hours." Half-life is the time to halve the dose, not eliminate it; three to five half-lives are needed for clinical clearance, and the receptor effect on sleep architecture outlasts even that Landolt 1995. Third: "I'm tolerant, so caffeine doesn't disrupt my sleep any more." Tolerance affects the subjective alerting and anxiogenic effects more than the sleep-architecture effect; chronic users show some adaptation in adenosine receptor density but the basic sleep-disruption signal persists Weibel 2020.

audience

Several populations live at the slow-clearance end of the distribution and need a more conservative cut-off than the population default. Women using combined oral contraceptives have roughly doubled half-life (~10 hours) Abernethy and Todd 1985. Pregnancy clearance approaches one-third of baseline by the third trimester Knutti 1981. Non-smoking CYP1A2 CC homozygotes (estimated 10–15% of European-ancestry populations) clear caffeine measurably slower than AA homozygotes Sachse 1999. ADORA2A risk-genotype carriers (~30%+ of the population) are at elevated risk of anxiety responses regardless of clearance speed Childs 2008. Older adults clear caffeine slightly slower on average; adolescents, who are still circadian-shifted later than adults, are particularly vulnerable to bedtime intrusion. By contrast, heavy smokers clear caffeine ~50% faster — but the moment they quit, half-life renormalises over a few days and they typically find their habitual caffeine dose now keeps them awake Carrillo and Benitez 2000.

practicalities

Self-identifying as a slow metaboliser without genotyping uses three signals: (1) caffeine subjectively "lasts longer" than peers describe; (2) afternoon coffee predictably costs sleep that night; (3) anxiety or palpitations from a moderate dose. Genotyping (23andMe historically reported rs762551; consumer pharmacogenomic panels still do) is cheap, but the behavioural test — moving the cut-off back by 2 hours for two weeks and tracking sleep — is more informative because it captures the joint effect of genotype, contraceptive use, smoking status and current medications. Caffeine doses come in widely variable forms: 8 oz drip coffee is roughly 95 mg, espresso shot 60–80 mg, black tea 40–70 mg, green tea 25–50 mg, energy drinks 80–300 mg, pre-workout supplements often 200–400 mg per serving. Decaf is not zero — it usually retains 2–15 mg per cup. The 400 mg/day EFSA ceiling translates to roughly 4 standard coffees per day, with single doses kept under 200 mg and none in the post-noon window for average metabolisers EFSA 2015.

failure-modes

Common screwups. Trying to cut off at 6 pm and concluding "caffeine doesn't affect me" because subjective sleep latency feels normal — but objective sleep architecture is still degraded for several more hours Drake 2013. Quitting smoking without adjusting caffeine, then attributing the resulting insomnia and anxiety to nicotine withdrawal when much of it is unmasked caffeine effect at the new (slower) clearance rate Carrillo and Benitez 2000. Starting an oral contraceptive or fluvoxamine without realising baseline caffeine dose has become functionally doubled. Treating decaf as zero-caffeine when it isn't, particularly for very slow metabolisers stacking 4–5 decafs through the evening. Trusting tolerance: habitual users still show measurable sleep disruption — the felt experience habituates faster than the physiology Clark and Landolt 2017 Weibel 2020.

stakes

Felt-experience consequence of ignoring half-life over months and years. In the population-default slow metaboliser drinking 2–3 coffees per day with the last around 3 pm: objective sleep efficiency drops several percentage points, slow-wave sleep is reduced by 15–30% on caffeine-exposed nights, total sleep time falls by 30–60 minutes Clark and Landolt 2017. This is the substrate for the chronic daytime fatigue that drives the next morning's coffee — a self-perpetuating loop in which caffeine compensates for the sleep deficit caffeine caused, with the drinker unaware of the causal direction. In ADORA2A-sensitive users, the anxiety load is constant and attributed to "stress" or "anxiety disorder" when its proximal cause is the daily dose Childs 2008. Over years, the chronic sleep restriction tracks with the longevity-relevant outcomes that follow chronic sleep restriction generally, but the dose-response is shallow at the individual level. Brain imaging shows reversible reductions in grey matter volume in the medial temporal lobe over 10 days of daily caffeine intake, normalising during washout Lin 2021.

payoff

Adoption of half-life-aware timing — typically cutting off 8–10 hours before bed, earlier for slow metabolisers — produces measurable polysomnography changes within the first sober night: shorter sleep latency, more slow-wave sleep, less fragmentation Landolt 1995. The subjective shift takes 1–2 weeks because habitual users have rebuilt their baseline expectations around the impaired sleep state. Reported timecourse from clinical trials and behavioural sleep interventions: within 3–5 days, easier sleep onset and fewer 3 am wakings; within 2 weeks, an unmasked baseline daytime alertness that does not require afternoon caffeine to maintain; within months, a stable lower daily caffeine total (because the morning dose is now sufficient). The anxiety reduction for ADORA2A carriers is faster — within hours of removing the dose. The catch: an established 4-coffee-per-day habit going to 1-coffee-at-7am produces 1–3 days of withdrawal — headache, low mood, sluggishness — and a clean two-week trial is what reveals the steady-state benefit.

out-of-scope

Adjacent topics not covered here: chronic caffeine withdrawal as a clinical syndrome; caffeine's metabolic effects (glucose tolerance, lipolysis); ergogenic dosing for endurance and strength sport; coffee as a beverage (polyphenols, chlorogenic acids); long-term cardiovascular epidemiology of habitual coffee consumption; caffeine and pregnancy beyond clearance kinetics; caffeine in children/adolescents.

The credibility range

Optimist case

The pharmacokinetic story is solid: CYP1A2 variation is real, large, and clinically actionable; the modifiers (smoking, OCP, pregnancy, fluvoxamine/ciprofloxacin) are documented across decades of pharmacology research Carrillo and Benitez 2000. The sleep-architecture effect is consistently demonstrated at polysomnography, with the canonical Drake 2013 trial showing 400 mg caffeine 6 hours pre-bed costs roughly an hour of objective sleep Drake 2013. Multiple replications from the same labs (Landolt and colleagues) confirm that morning caffeine alters evening EEG spectral power Landolt 1995. The recommendation — cut off 8–10 hours pre-bed, earlier if you have a known slow-clearance modifier — is mechanistically grounded, empirically supported, and zero-cost to test individually. The ADORA2A-anxiety link replicates across independent samples Childs 2008. The benefit at the population level is non-trivial: sleep restriction is a major mediator of fatigue, mood and metabolic complaints in the working population, and a meaningful fraction of that is iatrogenic — caused by mis-timed caffeine.

Skeptic case

Effect sizes are modest in absolute terms. Drake 2013's 6-hour cut-off cost ~1 hour of total sleep at 400 mg — but at 200 mg or 100 mg the effect is smaller, and habitual heavy users may have partially compensated. The CYP1A2*1F (rs762551) polymorphism's effect size on baseline (non-induced) caffeine clearance is real but small — most variance comes from smoking, OCP and pregnancy, all of which are observable without genotyping Sachse 1999. The polygenic GWAS hits for caffeine consumption (AHR, CYP1A2 region) capture habit not individual half-life precisely Cornelis 2011. Many users report perfectly adequate sleep with afternoon caffeine; while objective architecture may differ from their subjective report, the long-term clinical consequence of a 10% reduction in slow-wave sleep on a person who is otherwise healthy is plausibly small. Tolerance does shift the sleep-disruption magnitude in chronic users Weibel 2020. The anxiety effect via ADORA2A is dose-dependent and shows up most clearly at supra-habitual doses; the typical 1–2 cup/day user without anxiety symptoms does not need genotyping. The 8–10 hour rule is therefore a defensible default rather than a clean dose-response prescription, and population variation means many users will find shorter or longer cut-offs match their own observation.

Author's call

The half-life story is settled science with directly actionable downstream recommendations. The strongest two interventions a typical reader can act on are: (1) cut caffeine off at least 8 hours before bedtime, and earlier (morning-only) if they use OCPs, are pregnant, recently quit smoking, or take a CYP1A2 inhibitor; (2) keep daily total under 400 mg and single doses under 200 mg. The behaviour test — moving the cut-off back two hours for two weeks and tracking sleep — is more informative than genotyping for most readers. Evidence rating: 4 — multiple consistent RCTs anchor the sleep effect; pharmacokinetic variation has decades of clinical pharmacology behind it; ADORA2A-anxiety link is replicated; the only reason it isn't 5 is that the field has not produced large pragmatic trials of "move your cut-off" as an intervention. Controversy: 1 — the disagreement is mostly at the margin of whether everyone needs an aggressive cut-off, not whether caffeine timing matters.

Stakeholder and incentive map

Coffee industry and energy-drink manufacturers have a clear commercial incentive to downplay timing and dose limits and emphasise tolerance. National Coffee Association communications consistently emphasise the moderate-consumer safety story EFSA 2015 and rarely lead with sleep architecture.
Sleep clinicians and AASM-aligned researchers (Landolt, Drake, Roth, Reichert) have driven the polysomnography literature and consistently recommend conservative cut-offs Clark and Landolt 2017. Sleep medicine as a specialty is structurally aligned with surfacing sleep harms.
Pharmacogenomics consumer companies (23andMe historically, current PGx panels) have a commercial interest in foregrounding the CYP1A2 genotype story, sometimes overstating actionability.
Performance / wellness communities (sport nutrition, biohacking podcasts) have surfaced the half-life framing aggressively over the past decade — credit where due, the half-life and cut-off advice that reached general audiences came from this community before mainstream guidelines caught up. Risk: the community-amplified version sometimes treats the population default as universal law without acknowledging the variation it is trying to manage.
Regulators (EFSA, FDA) sit at 400 mg/day for healthy adults with caveats; they have not codified a bedtime cut-off in regulatory language though sleep researchers consistently recommend one.

Population variability

CYP1A2 rs762551 genotype. AA fast metabolisers vs CC slow metabolisers — population frequencies vary by ancestry; in European-ancestry samples roughly 45% AA, 45% AC, 10% CC. Effect on caffeine clearance is largest under induction (smoking) and smaller in non-smokers Sachse 1999 Cornelis 2011.
Smoking status. The single largest non-genetic modifier — heavy smokers clear caffeine ~50% faster; effect reverses within 4–6 days of cessation Carrillo and Benitez 2000.
Oral contraceptives. Roughly double half-life via ethinyl oestradiol CYP1A2 inhibition Abernethy and Todd 1985 Granfors 2005.
Pregnancy. Third-trimester clearance is one-third of pre-pregnancy Knutti 1981.
Age. Mild slowing in older adults. Adolescents have similar clearance to adults but more bedtime vulnerability from later circadian phase.
Concurrent medications. Fluvoxamine (5–10x AUC increase), ciprofloxacin (~2x), fluconazole, mexiletine — all CYP1A2 inhibitors; carbamazepine, rifampicin, phenytoin — inducers Carrillo and Benitez 2000 Jeppesen 1996.
ADORA2A rs5751876. Risk allele carriers (~30%+ of population) show stronger anxiety response at typical doses Alsene 2003 Childs 2008.
Tolerance. Chronic users develop partial tolerance to alerting and anxiety effects; sleep-architecture effects are more resistant to tolerance Weibel 2020.

Knowledge gaps

Several. The dose-response for cut-off timing has been pinned at 400 mg in Drake 2013 but no comparable trial spans the full grid of dose (100–400 mg) × clearance speed (fast/slow metaboliser) × cut-off (0–10 h pre-bed); the population default of 8–10 hours is a reasonable interpolation rather than a directly trialed point. Long-term outcomes of moving caffeine to morning-only have not been studied in a pragmatic RCT — most evidence is mechanistic and short-term. The ADORA2A genotype work has been replicated in modest-sized samples but lacks a large-scale population biobank confirmation. The interaction between CYP1A2 induction (smoking, cruciferous vegetables, grilled meat) and adenosine pharmacodynamics is incompletely mapped. Reversibility of grey matter changes with caffeine cessation has been shown short-term Lin 2021 but long-term consequences are unclear. Finally, the question of whether "morning-only" cleanly translates to the chronotype-shifted young adult population (whose biological morning is, say, 11 am) is undocumented.

Scope and narrowing. The brief named four consequences — sleep onset, sleep architecture, anxiety, timing of consumption — and the entry covers all four end-to-end. Sleep onset and architecture are the headline (anchored to Drake 2013 and Landolt 1995). Anxiety lands in the audience and contraindications sections via the ADORA2A variant work. Timing relative to bedtime is the protocol. Holistic scoring then adds the downstream dimensions — energy, focus, mood (sleep-mediated), modest health-short-term and longevity, marginal beauty-cumulative — that follow from the substance even though the brief didn't name them. No silent dropping.

Rating difficulties. Sleep was scored 4 rather than 5 because the substance here is the timing intervention, not caffeine cessation outright — strong but not dominant. Energy at 3 is the dominant felt-experience win for typical users, separable from the morning-coffee energy that the intervention preserves. Effort burden at 2 (not 1) reflects the persistent daily decision plus the 1–3 day withdrawal window for established habits; calling it 1 would understate the typical user's experience. Evidence at 4 (not 5) because no large pragmatic RCT of "move your cut-off" has run end-to-end — the evidence is anchored on canonical sleep-lab work that proves the mechanism rather than on a pragmatic effectiveness trial.

Hard decision on action verb. Considered know (since half-life is fundamentally a piece of knowledge) but landed on do because the actionable surface — set a personal cut-off and hold it — is the load-bearing reader takeaway. The article reflects that with the two-week behavioural test as the central protocol.

Excluded from this entry.

Caffeine cessation as a strategy. Different substance, different decision; this entry is about timing the dose, not removing it.
Caffeine in sport performance. Ergogenic dosing and the genetics of athletic response to caffeine are a separate frame. Future entry candidate.
Coffee as a beverage. Polyphenols, chlorogenic acids, the long-term cardiovascular epidemiology — those ride on the coffee matrix, not the caffeine molecule. Separate entry.
Caffeine in pregnancy beyond the timing rule. The 200 mg/day pregnancy ceiling is mentioned in contraindications; the broader fetal-exposure literature warrants its own entry.
Adolescent caffeine. Circadian-shifted bedtimes plus developing brains is a separate population worth its own treatment.
Chronic caffeine withdrawal as a clinical syndrome. Mentioned briefly under out-of-scope; would benefit from its own entry covering DSM-5 criteria, treatment, and timecourse.

Future-link candidates. Sleep debt; circadian alignment / morning light; slow-wave sleep biology; ADORA2A and individual stimulant response (if such an entry is ever spun up); coffee-the-beverage; pre-workout supplement safety.

Notes on evidence used. The Reichert 2022 review and Lin 2021 grey-matter finding sit in the dossier as supporting context but didn't earn a place in the article — the article keeps the focus narrowly on timing rather than on adenosine receptor plasticity and brain-imaging endpoints. The Yang 2010 and Smith 2002 reviews and Granfors 2005 on OCP CYP1A2 inhibition similarly back the dossier rather than the article; Cornelis 2006 and Cornelis 2011 are kept in the dossier as the population-genetics anchor.

Status set to draft pending review.